Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

West China Hospital is the lead sponsor of 169 current clinical trials in our China register. 106 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Sintilimab, Tislelizumab and Afatinib. The most-studied condition is Liver Cancer.

ClinicalTrials.gov trials by status

Recruiting10663%
Not yet open4325%
Active, closed1811%
By invitation21%

Trials by phase

Not applicable3722%
Phase 13621%
Phase 23320%
Observational2716%
Phase 1/2169%
Phase 385%
Phase 2/353%
Phase EARLY_PHASE142%
Phase 432%

Clinical trials sponsored by West China Hospital

169 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
The Application of Artificial Intelligence in Wrist and Hand Joint Ultrasound NCT06883669 · Education, Joint Diseases	Observational	Recruiting	2021-01	China
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors NCT07035249 · DCSZ11, Solid Tumors, HNSCC Drug: DCSZ11	Phase 1/2	Recruiting	2025-12	China
Identifying Local Field Potential Biomarkers for Obsessive-compulsive Disorder Treatment With Deep Brain Stimulation NCT06542224 · Obsessive-Compulsive Disorder	Not applicable	Recruiting	2024-08	China
Assessment System for Sarcopenia Based on Ultrasonographic Data NCT06199856 · ClinicalTrials.gov ↗ · Sarcopenia, Ultrasound	Observational	Recruiting	2020-10	China
Non-pharmacological Auditory and Somatosensory Stimulation in Anesthetic Emergence NCT07339618 · ClinicalTrials.gov ↗ · General Anesthetic, Electroencephalographic	Not applicable	Recruiting	2025-10	China
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors NCT07583654 · ClinicalTrials.gov ↗ · mRNA Vaccine, Solid Tumor Cancer, Peptides	Phase 1	Recruiting	2026-07	China
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer Drugs: Adebrelimab, Nalirifox	Phase 1/2	Recruiting	2026-04	China
Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy NCT07260526 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Recruiting	2025-10	China
Effect of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Surgery NCT06405776 · ClinicalTrials.gov ↗ · Colorectal Cancer Drug: Lidocaine	Not applicable	Recruiting	2023-06	China
Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery NCT07316101 · ClinicalTrials.gov ↗ · Pituitary Adenoma, Craniopharyngioma	Not applicable	Recruiting	2026-03	China
Online Sharing for Head & Neck Cancer Support NCT07766226 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Not applicable	Recruiting	2026-08	China
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma NCT07482059 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 1/2	Recruiting	2026-02	China
Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol NCT05369442 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Observational	Recruiting	2022-05	China
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC NCT06742424 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC) Drug: Bevacizumab	Phase 2	Recruiting	2024-10	China
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma NCT07072351 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy	Phase 1/2	Recruiting	2025-09	China
Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection NCT07295275 · ClinicalTrials.gov ↗ · Liver Cancer	Observational	Recruiting	2026-03	China
Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China NCT07518966 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Observational	Recruiting	2025-06	China
Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection NCT06219096 · ClinicalTrials.gov ↗ · Malignant Tumor of Liver, Randomized Controlled Trial	Not applicable	Recruiting	2023-12	China
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer NCT07101679 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	2025-04	China
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration NCT07776522 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD Drug: Aflibercept	Phase 2	Recruiting	2026-08	China
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) NCT05447702 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Apatinib, Camrelizumab, Cyclophosphamide	Phase 2	Recruiting	2022-11	China
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy NCT07545967 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma HNSCC Drug: Chidamide	Phase 1	Recruiting	2026-04	China
Individualized ANH for Non-cardiac Surgery NCT06399536 · ClinicalTrials.gov ↗ · Transfusion Related Complication, Hemodilution	Not applicable	Recruiting	2024-06	China
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC NCT07565740 · ClinicalTrials.gov ↗ · HPV-positive Oropharyngeal Squamous Cell Carcinoma Drug: Tislelizumab	Phase 1	Recruiting	2026-05	China
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer NCT07703163 · ClinicalTrials.gov ↗ · Solid Tumor, SGLT 2 Inhibitors Drug: Canagliflozin	Phase 1	Recruiting	2026-09	China
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients. NCT07339774 · ClinicalTrials.gov ↗ · Radiotherapy-induced Oral Mucositis	Phase 2	Recruiting	2026-03	China
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT NCT06664996 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	2024-10	China
Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS) NCT06345898 · ClinicalTrials.gov ↗ · X Linked Retinoschisis	Phase EARLY_PHASE1	Recruiting	2023-11	China
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation NCT06542094 · ClinicalTrials.gov ↗ · Major Depressive Disorder, Treatment Resistant Depression	Not applicable	Recruiting	2024-08	China
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy NCT07562841 · ClinicalTrials.gov ↗ · Advanced Melanoma Drug: Toripalimab	Phase 1	Recruiting	2026-04	China
Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy NCT06341270 · ClinicalTrials.gov ↗ · Liver Cancer	Not applicable	Recruiting	2024-05	China
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma NCT06438822 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Phase 2	Recruiting	2024-08	China
Assessment System of Sarcopenia in Lung Cancer Patients NCT06327594 · ClinicalTrials.gov ↗ · Sarcopenia, Lung Cancer, Ultrasound	Observational	Recruiting	2023-11	China
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery NCT07724106 · ClinicalTrials.gov ↗ · Ovarian Cancer, mRNA Vaccine	Phase 1	Recruiting	2026-09	China
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies NCT07763301 · ClinicalTrials.gov ↗ · Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC) Drug: YMN-136 vaccine	Phase 1	Recruiting	2026-08	China
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma NCT06831175 · ClinicalTrials.gov ↗ · Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer	Phase 2	Recruiting	2025-03	China
A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) NCT07035626 · ClinicalTrials.gov ↗ · Radiation-induced Xerostomia Drug: Spermidine	Phase 1/2	Recruiting	2025-06	China
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study NCT07457281 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma HNSCC Drugs: GV20-0251, Sintilimab	Phase 1	Recruiting	2026-04	China
IMP3-saRNA Vaccine in Advanced NSCLC NCT07561723 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 1	Recruiting	2026-04	China
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma NCT06950827 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatectomy, Laparoscopic Hepatectomy	Observational	Recruiting	2025-04	China
Efficacy of TEAS on Chronic Pain and Survival in Patients Undergoing Hepatectomy NCT06406244 · ClinicalTrials.gov ↗ · Liver Cancer	Not applicable	Recruiting	2024-04	China
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery NCT07676890 · ClinicalTrials.gov ↗ · Ovarian Cancer, mRNA Vaccine	Phase 1	Recruiting	2026-09	China
AI App for Management of Atopic Dermatitis NCT06362629 · ClinicalTrials.gov ↗ · Atopic Dermatitis, Artificial Intelligence	Not applicable	Recruiting	2024-09	China
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC NCT06627712 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Phase 3	Recruiting	2024-11	China
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer NCT06341296 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Bevacizumab, Irinotecan liposome, Ivonescimab	Phase 2	Recruiting	2024-06	China
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) NCT06242418 · ClinicalTrials.gov ↗ · Colon Cancer Drugs: Folfoxiri, Xelox	Phase 2	Recruiting	2024-03	China
Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients NCT07510308 · ClinicalTrials.gov ↗ · pMMR/MSS Advanced Colorectal Cancer	Phase 1	Recruiting	2026-06	China
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus NCT06741982 · ClinicalTrials.gov ↗ · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy Drugs: Afatinib, Lysogenic HSV virus, Tislelizumab	Phase 1	Recruiting	2024-12	China
Tai Chi for Cancer-Related Fatigue During Radiotherapy in Patients With Head and Neck Cancer NCT07809776 · ClinicalTrials.gov ↗ · Head and Neck Neoplasms, Cancer-related Fatigue	Not applicable	Recruiting	2026-09	China
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer NCT07076823 · ClinicalTrials.gov ↗ · Colorectal Cancer, SGLT-2 Inhibitor Drug: Canagliflozin	Phase 1	Recruiting	2025-07	China
Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery NCT04316039 · ClinicalTrials.gov ↗ · Low-grade Glioma	Phase 2/3	Recruiting	2018-04	China
Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR) NCT07070622 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	2024-11	China
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC NCT07572864 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drug: Engineered Mitochondrial Vaccine	Phase 2	Recruiting	2026-06	China
Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy NCT07452848 · ClinicalTrials.gov ↗ · Gallbladder Diseases, Cholelithiasis	Observational	Recruiting	2026-03	China
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors NCT07560943 · ClinicalTrials.gov ↗ · Cancer	Phase 1	Recruiting	2026-04	China
A Study of Online Follow-up in Patients With Papillary Thyroid Cancer NCT06800482 · ClinicalTrials.gov ↗ · Thyroid, Papillary Thyroid Cancer	Not applicable	Recruiting	2024-08	China
Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients NCT07282483 · ClinicalTrials.gov ↗ · Radiation-induced Oral Mucositis	Phase 2	Recruiting	2026-03	China
Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World NCT07105631 · ClinicalTrials.gov ↗ · Colorectal Cancer	Observational	Recruiting	2025-07	China
YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment NCT07409805 · ClinicalTrials.gov ↗ · Colorectal Cancer Drug: YMN-136 vaccine	Phase 1	Recruiting	2026-05	China
ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer NCT07081074 · ClinicalTrials.gov ↗ · Radiation Dermatitis	Not applicable	Recruiting	2025-07	China
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS NCT07612774 · ClinicalTrials.gov ↗ · Coronary, Coronary Artery Disease Drug: Evolocumab	Phase 4	Recruiting	2026-05	China
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial) NCT06859684 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab	Phase 2	Recruiting	2025-03	China
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study NCT07020247 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy	Phase 3	Recruiting	2024-11	China
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I NCT06519552 · ClinicalTrials.gov ↗ · Mucopolysaccharidosis Type I	Phase 1	Recruiting	2024-07	China
Predicting Tumor Origin Based on Deep Learning of Lymph Node Puncture Cytology NCT06810349 · ClinicalTrials.gov ↗ · Lymph Nodes With Tumor Metastasis	Observational	Recruiting	2024-11	China
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors NCT06927297 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Malignancies, Advanced Solid Malignancies Drug: Engineered Mitochondrial Vaccine	Phase 1	Recruiting	2025-05	China
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS) NCT07538479 · ClinicalTrials.gov ↗ · Solid Tumors, Solid Malignancies, Cold Exposure	Phase 1	Recruiting	2026-04	China
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma NCT06753747 · ClinicalTrials.gov ↗ · Esophagus Cancer Drugs: Afatinib, Palbociclib	Phase 1/2	Recruiting	2025-09	China
Early Warning and Stratified Diagnosis of Postoperative Respiratory Failure Based on Ventilator Waveform Image Features NCT07799636 · ClinicalTrials.gov ↗ · Postoperative Respiratory Failure	Observational	Recruiting	2025-12	China
The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms NCT07310056 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery	Not applicable	Recruiting	2026-01	China
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors NCT07563972 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Neoplasm	Phase 1	Recruiting	2026-05	China
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis NCT07353671 · ClinicalTrials.gov ↗ · Radiation-induced Dermatitis	Phase 2/3	Recruiting	2026-03	China
Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients NCT06437158 · ClinicalTrials.gov ↗ · Lymphatic Malformation Drug: Bleomycin	Phase 2	Recruiting	2023-03	China
Wireless Wearable Home Prehabilitation for Older Adults With NSCLC NCT07809763 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery	Not applicable	Recruiting	2026-09	China
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC NCT06132698 · ClinicalTrials.gov ↗ · NSCLC Associated With Leptomeningeal Metastases Drug: Tislelizumab	Phase 2	Recruiting	2023-11	China
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer NCT05640609 · ClinicalTrials.gov ↗ · Stomach Neoplasm	Phase 1/2	Recruiting	2023-03	China
Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer NCT07076836 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC), Immune Checkpoint Blockade, Electroacupuncture	Not applicable	Recruiting	2026-08	China
A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma Drug: GV20-0251	Phase 1	Recruiting	2025-09	China
Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy NCT07467083 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 3	Recruiting	2026-03	China
Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy NCT06778460 · ClinicalTrials.gov ↗ · Postoperative Chronic Pain	Not applicable	Recruiting	2023-05	China
H101 Plus TACE for r/m HNSCC NCT07398664 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE Drug: H101	Phase 2	Recruiting	2026-03	China
Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma NCT07077356 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 1	Recruiting	2025-08	China
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma NCT06950814 · ClinicalTrials.gov ↗ · Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy	Observational	Recruiting	2025-04	China
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma NCT07492914 · ClinicalTrials.gov ↗ · Resectable Head and Neck Squamous Cell Carcinoma Drugs: Sacituzumab Govitecan, Tagitanlimab	Phase 2	Recruiting	2026-05	China
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer NCT07636798 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 1/2	Recruiting	2026-06	China
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors NCT07567222 · ClinicalTrials.gov ↗ · Malignant Tumor Drug: Regorafenib	Phase 1	Recruiting	2026-06	China
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma NCT06798363 · ClinicalTrials.gov ↗ · Infantile Hemangioma	Phase 2/3	Recruiting	2025-01	China
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC NCT07295262 · ClinicalTrials.gov ↗ · Liver Cancer, Adult	Phase EARLY_PHASE1	Recruiting	2026-01	China
Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer NCT07064577 · ClinicalTrials.gov ↗ · Radiation Dermatitis	Not applicable	Recruiting	2025-07	China
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection NCT07295340 · ClinicalTrials.gov ↗ · Liver Cancer	Observational	Recruiting	2026-01	China
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer NCT06482086 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma Drugs: Anlotinib, Apatinib, Cabozantinib	Phase 2	Recruiting	2021-06	China
Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury NCT07635277 · ClinicalTrials.gov ↗ · Radiation-Induced Skin Injury	Phase 1	Recruiting	2026-06	China
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma NCT07182565 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy Drug: TS-1)	Phase 1/2	Recruiting	2025-11	China
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC NCT06742411 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer Drugs: Sintilimab, Xelox	Phase 1/2	Recruiting	2024-12	China
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07381075 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: Becotatug Vedotin, Ivonescimab, Penpulimab	Phase 2	Recruiting	2026-07	China
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. NCT07053072 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 1	Recruiting	2025-10	China
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis NCT07567235 · ClinicalTrials.gov ↗ · Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma	Phase 1	Recruiting	2026-06	China
Physiological Studies in the Prone Position in Patients With ARDS NCT06586736 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome, Mechanical Ventilation, Prone Positioning	Observational	Recruiting	2023-09	China
A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management NCT06663956 · ClinicalTrials.gov ↗ · Cancer Pain	Phase 3	Recruiting	2024-11	China
Clinical Characteristics and Epidemiology of Chronic Critically Ill Patients in China NCT07372742 · ClinicalTrials.gov ↗ · Chronic Critically Ill	Observational	Recruiting	2025-03	China

Showing the 100 most recently updated of 169 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in West China Hospital trials

76 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 36 more in the trial list above.

Conditions in West China Hospital trials

211 conditions

Liver Cancer7 Head and Neck Squamous Cell Carcinoma6 Immunotherapy6 Colorectal Cancer4 Non-Small Cell Lung Cancer (NSCLC)4Rehabilitation4Thoracic Surgery4HNSCC3mRNA Vaccine3Rectal Cancer3Radiation Dermatitis3Radiation-induced Oral Mucositis2Solid Tumors2 Sarcopenia2 Ultrasound2 Solid Tumor Cancer2 Pancreatic Ductal Adenocarcinoma (PDAC)2 Coronary Artery Disease2 Thyroid Cancer2Infantile Hemangioma (IH)2Gastroesophageal Junction Adenocarcinoma2Hypofractionated Radiotherapy2Portal Hypertension2 Head and Neck Squamous Cell Carcinoma HNSCC2

By trial register

Register	Trials	Recruiting
Clinical trials in China	169	106

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Liver Cancer

Sponsor	Trials
Zhiyong Huang	1

Sponsors with the most current trials registered for this condition.

Questions about West China Hospital trials

How many clinical trials does West China Hospital sponsor?

West China Hospital is the lead sponsor of 169 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are West China Hospital trials recruiting?

Yes. 106 of its 169 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is West China Hospital testing?

Its current trials name 76 drugs and biologicals as interventions. The most frequent are Sintilimab (4), Tislelizumab (4), Afatinib (3), Apatinib (3) and Ivonescimab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

West China Hospital clinical trials